Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29150569 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2CYP3A4MAPTLMNA | |
| SCHEMBL31426578 | 0.80 | HTT (0.41) | SMN1; SMN2MAPTNPSR1HTTALDH1A1 | |
| SCHEMBL23089593 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2CYP3A4MAPTLMNA | |
| SCHEMBL18299967 | 0.77 | KMT2A (0.49) | SMN1; SMN2USP2CYP3A4MAPTLMNA | |
| SCHEMBL23089267 | 0.76 | ALDH1A1 (0.37) | USP2MAPTLMNANPSR1HTT | |
| SCHEMBL30700884 | 0.76 | ALDH1A1 (0.37) | USP2MAPTLMNANPSR1HTT | |
| SCHEMBL14661117 | 0.74 | CA12 (0.45) | SMN1; SMN2MAPTLMNANPSR1HTT | |
| SCHEMBL14037506 | 0.72 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2CYP3A4MAPTLMNA | |
| SCHEMBL844417 | 0.72 | CYP2C9 (0.50) | SMN1; SMN2CYP3A4MAPTLMNANPSR1 | |
| SCHEMBL23088380 | 0.72 | HTT (0.46) | SMN1; SMN2CYP3A4MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11926625-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4301756-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022187856-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | SMN1; SMN2 2980/4885USP2 2116/4885CYP3A4 3156/4885 |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | HIPK1, PDXK, IP6K1 | SMN1; SMN2 2980/4885USP2 2116/4885CYP3A4 3156/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
| US-11926625-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | SMN1; SMN2 2980/4885USP2 2116/4885CYP3A4 3156/4885 |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | SMN1; SMN2 2709/4885USP2 2229/4885CYP3A4 3149/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | SMN1; SMN2 2980/4885USP2 2116/4885CYP3A4 3156/4885 |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, SIK1 | SMN1; SMN2 2011/4885USP2 3117/4885CYP3A4 4152/4885 |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, IP6K1, PDXK | SMN1; SMN2 3674/4885USP2 2123/4885CYP3A4 2704/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885USP2 1493/4885CYP3A4 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.